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Abstract
Purpose:  Robotic  stereotactic  body  radiation  therapy  (SBRT)  for  the  treatment  of  hepatocellular
carcinoma  requires  the  perilesional  implant  of  gold  ﬁducial  markers  for  detection  by  scopy.  The
purpose of  this  study  is  to  determine  whether  the  implant  of  gold  ﬁducial  markers  is  still  possible
and, if  so,  with  which  imaging  technique  and  with  what  results.
Materials  and  methods:  This  is  a  prospective  study  based  on  the  implant  of  ﬁducial  markers
in the  liver  in  our  department  for  a  treatment  by  SBRT  for  a  hepatocellular  carcinoma  in  38
patients (49  lesions  to  treat)  over  a  period  of  one  year.  As  the  ﬁrst  choice,  it  consisted  of
sonographic  guidance  and,  if  not  possible,  CT-scan  guidance  was  used.
Results:  The  mean  number  of  ﬁducial  markers  implanted  per  procedure  was  2.68(±  0.61)  with
almost exclusive  sonographic  guidance  (36  out  of  38  patients  or  95%  of  the  patients).  The
mean distance  between  the  markers  and  the  lesion  was  32  mm  (±  11  mm)  and  that  between  the
markers was  17  mm  (±  7  mm).
Conclusion:  SBRT  is  being  evaluated  for  the  treatment  of  liver  lesions.  The  radiologist  has  an
important  role  to  play  since  the  implant  of  ﬁducial  markers  in  the  liver  is  indispensable.  It  is
almost always  possible  with  sonographic  guidance,  including  for  lesions  not  accessible  to  micro-
biopsies, a  treatment  by  radiofre
CT-scan.
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Hepatocellular  carcinoma  (HCC)  is  the  most  common  pri-
ary  tumour  of  the  liver,  generally  developed  within  a
ontext  of  chronic  liver  disease,  most  often  cirrhosis  (90%  of
he  cases  including  70%  of  alcoholic  origin  in  France).  With
00,000  new  cases  per  year  in  the  world  and  7000  in  France
annual  incidence  of  11/100,000  in  men  and  2/100,000  in
omen),  HCC  is  the  5th  most  common  cancer  in  the  world
1].
The  reference  treatment  for  localised  HCC  remains  the
iver  transplant  or  excision.  Radiofrequency  and  chemoem-
olisation  are  validated  local  treatments  while  waiting  for
 liver  transplant  or  in  inoperable  patients.
Until  now,  conformational  radiotherapy  has  had  a  limited
lace  in  the  treatment  of  localised  HCC  due  to  the  major
xposure  of  healthy  liver  tissue  [2—4].  The  development  of
igh  conformity  radiotherapy  associated  with  live  imaging
ay,  in  this  type  of  lesion,  allow  for  the  delivery  of  a higher
ose  while  limiting  the  exposure  of  the  adjacent  healthy
issue  [5]  and  thereby  propose  an  alternative  ‘‘curative’’
olution  for  the  inoperable  patient  [6,7].  Stereotactic  body
adiation  therapy  (SBRT)  by  Cyberknife  is  a  new  technology
roviding  new  therapeutic  possibilities.
SBRT  by  Cyberknife® in  the  treatment  of  liver  lesions
elivers  100  to  200  photon  beams  of  6  MV  [5,8]  (Fig.  1)
ith  a  permanent  control  of  the  position  of  the  tumour.  It
equires  the  implant  of  gold  ﬁducial  markers  in  the  periph-
ry  of  the  tumour  for  detection  by  scopy.  These  ﬁducial
t
i
a
igure 1. Planning of the treatment of two synchronous lesions.G.  Oldrini  et  al.
arkers  should  ideally  be  situated  2  to  5  cm  around  the
esion  to  treat.  In  this  way,  the  tumour  moves  in  the  same
ay  as  the  ﬁducial  markers  so  that  the  respiratory  tracking
odel  is  adapted.  The  patients  for  which  SBRT  is  proposed
n  a  multi-disciplinary  meeting  (MDM)  are  mainly  patients
n  which  other  therapeutic  means  are  counter-indicated.
n  fact,  the  contra-indications  may  be  due  to  the  general
tate  of  the  patient,  in  particular  the  possibilities  of  general
naesthetic  as  well  as  contra-indications  due  to  the  topog-
aphy  of  the  lesions  and  in  particular  lesions  of  the  vault  not
ccessible  to  a  radiofrequency.
aterials and methods
his  is  a  prospective  study  based  on  the  implant  of  gold  ﬁdu-
ial  markers  in  the  liver  in  our  department  for  treatment  by
BRT  for  hepatocellular  carcinoma  in  38  patients  over  one
ear.  Fourty-nine  lesions  had  to  be  treated.  The  indication
or  treatment  by  SBRT  was  always  validated  in  MDM.
The  study  fell  within  the  usual  care  and  an  authorisation
y  the  local  ethics  committee  was  therefore  not  necessary.
he  gold  ﬁducial  markers  were  implanted  by  a  single  opera-
or  who  was  entrusted  with  the  study  of  the  feasibility  and
mplant.
Gold  ﬁducial  markers  3  mm  long  were  used.  They  were
ssembled  on  12  cm  syringes  and  a  calibre  of  18-gauges  with
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Discussion
SBRT  is  a  technique  that  is  still  being  developed  in  France
and  few  centres  are  equipped.  Nevertheless,  this  treatment
is  promising  and  may  be  a  resort  when  other  techniques
are  not  possible.  It  is  interesting  that  it  is  possible  to  treat
patients  in  which  radiofrequency  treatment  has  not  been
possible  due  to  the  topography  of  the  lesion.
The  involvement  of  the  radiologist  is  important  in  this
technique  since  they  enable  the  detection  of  the  lesion  with-
out  which  the  treatment  is  not  possible.  In  addition,  the
position  and  number  of  ﬁducial  markers  have  an  effect  on
the  treatment.  In  fact,  the  farther  the  ﬁducial  markers  from
the  lesion  and  the  fewer  the  number  of  ﬁducial  markers,
the  more  the  radiotherapist  will  have  to  take  considerable
margins  by  exposing  the  healthy  parenchyma  [9].  This  may
aggravate  the  liver  failure  in  cirrhotic  patients  with  a  high
Child-Pugh  score.
The  dose  delivered  during  the  treatment  was  from  30  to
45  Gy  in  3  or  4  sessions  over  10  days  (single  dose  prescrip-
tion  80%).  The  treated  target  was  the  macroscopic  volume
of  the  imaging  (Gross  Tumour  Volume  [GTV])  assessed  on
the  CT-scan  and  MRI  with  an  infraclinical  extension  margin
ranging  from  3  mm  to  1  cm  (Clinical  Target  Volume  [CTV])
and  a  safety  margin  of  2  to  3  mm  related  to  the  uncertainty
(Planning  Target  Volume  [PTV]).
In  this  study,  the  implant  of  ﬁducial  markers  was  never
rejected  due  to  the  topography  of  the  lesion  (by  either  using
sonography  guidance  or  CT-scan  guidance).  One  implant  of
liver  ﬁducial  markers  was  not  possible  due  to  persistent
and  abundant  ascitis.  Nevertheless,  the  implant  would  have
been  possible  if  an  approach  was  present  without  ascitis
(Fig.  3).
One  of  the  main  difﬁculties  in  sonography  is  to  be  able  to
space  the  different  ﬁducial  markers.  In  fact,  the  construc-
tor  indicates  that  the  minimum  space  between  2  ﬁducial
markers  should  be  2  cm  so  that  the  software  can  provide
translation  and  rotational  movement.  If  there  is  less  than
2  cm,  only  movement  in  translation  is  possible  although,Figure 2. Gold ﬁducial marker, 18-gauge syringe and plunger.
use  of  a  17-gauge  guide  (Fig.  2).  The  guide  either  used
Toshiba  Aplio  sonography  or  Philips  Brilliance  40  CT-scan.
The  ﬁrst  choice  was  sonography  and,  if  not  possible,  a  CT-
scan  was  used.  The  pre-procedure  imaging  ﬁle  comprised
a  CT-scan  and/or  a  liver  MRI.  An  acquisition  CT-scan  was
obtained  seven  days  after  the  implant  for  the  dosimetry
after  injection  of  iodine  contrast  agent  with  acquisitions  at
arterial  and  portal  times.  On  this  CT-scan,  a  single  operator
measured  the  distance  between  the  ﬁducial  markers  and  the
lesion  and  the  distance  between  the  ﬁducial  markers.
Statistical analysis
The  socio-demographic  criteria  were  studied.
The  number  of  procedures  not  carried  out  was  calculated
as  well  as  the  number  of  procedures  per  guidance  technique.
The  number  of  ﬁducial  markers  implanted,  the  distance
between  the  ﬁducial  markers,  the  distance  between  the
ﬁducial  markers  and  the  lesion  were  studied  with  mean  cal-
culations  as  well  as  the  standard  deviations  and  the  bounds.
Results
There  were  30  men  (79%)  and  8  women  (21%).  The  mean  age
was  69  years  (standard  deviation:  11.6  years)  with  extremes
of  47  and  85  years.
The  mean  number  of  ﬁducial  markers  implanted  per  pro-
cedure  was  2.68  with  a  standard  deviation  of  0.61  (between
1  and  3  ﬁducial  markers  implanted).
The  maximum  number  of  targets  detected  and  to  treat
were  2  in  11  patients  or  29%  of  the  patients.
The  mean  distance  between  the  ﬁducial  markers  and  the
lesion  was  32  mm  (standard  deviation:  11  mm,  [21—43  mm])
and  the  mean  distance  between  the  ﬁducial  markers  was
17.3  mm  (standard  deviation:  7  mm,  [10.3—24.3  mm]).  In
two  cases,  a  single  ﬁducial  marker  was  implanted  and  in  all
other  cases,  at  least  two  ﬁducial  markers  were  implanted
20  mm  apart.
In  36  of  the  38  patients  (95%),  the  procedures  were
carried  out  with  sonographic  guidance.  In  one  case,  the
procedure  used  CT-scan  guidance.  One  implant  of  ﬁducial
markers  in  the  liver  was  not  possible  due  to  persistent  and
abundant  ascitis.
Figure 3. Subcapsular HCC (small arrow) and approach for the
implant of ﬁducial marker with ﬁducial marker in place (big arrow)
without ascitis along the path.
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ften,  the  rotations  are  not  important  and  an  approximation
f  the  movement  with  the  translations  alone  may  be  sufﬁ-
ient.  Once  the  guide  is  installed,  it  is  fairly  complicated
o  have  this  margin  between  the  different  ﬁducial  mark-
rs  without  having  to  cross  the  liver  capsule  several  times,
ncreasing  the  risk  of  haemorrhage  in  patients  presenting
oagulation  disorders.
One  of  the  limits  of  sonography  guidance  is  due  to  the  fact
hat  the  lesions  aren’t  always  visible  by  sonography,  either
ue  to  a  very  heterogeneous  parenchyma  (hepatocellular
arcinoma  (HCC)  on  cirrhosis)  or  their  high  position,  with
nly  33  out  of  49  lesions  clearly  individualisable.  Neverthe-
ess,  with  the  initial  imaging,  it  is  always  possible  to  know
he  zone  in  which  the  ﬁducial  markers  have  to  be  implanted
o  as  to  be  within  5  cm  of  the  lesion.  In  one  case,  sonography
uidance  was  not  possible.  In  fact,  the  liver  was  rearranged
ue  to  a  past  history  of  liver  surgery  with  a  high  position  and
igestive  interpositions.  The  implant  was  therefore  carried
ut  with  sonography  guidance.
In  spite  of  the  altered  coagulation  assessments  in  most
atients,  there  were  no  secondary  complications  due  to  the
rocedure.  The  implant  of  liver  ﬁducial  markers  is  probably
ess  of  a  risk  than  liver  microbiopsies  although  this  has  to  be
ssessed  in  larger  series.
Only  three  ﬁducial  markers  or,  in  certain  cases,  two
ducial  markers  were  implanted  to  reduce  the  risk  of
aemorrhage.  In  fact,  the  platelets  were  often  around
0,000/mm3 with  a  prothrombin  time  at  60%  and  a
atient/control  ratio  of  1.4.  Thirty-ﬁve  ﬁles  had  at  least
wo  ﬁducial  markers  2  cm  apart  and,  in  two  cases,  a  single
ducial  marker  was  inserted  due  to  the  subcapsular  lesions
ithout  the  possibility  of  interposing  a  healthy  parenchyma
ith  ascitis  and  a  perturbed  coagulation  assessment  associ-
ted  with  thrombocytopenia  not  preventing  the  treatment
y  SBRT.  For  the  same  purpose,  in  case  of  double  liver  loca-
ion,  the  ﬁducial  markers  were  inserted  to  be  able  to  serve
wo  locations  as  soon  as  possible.  In  view  of  the  possibility
f  implanting  ﬁducial  markers  up  to  5  cm  around  the  lesion,
his  would  enable  the  use  of  the  same  ﬁducial  markers  for
esions  8  to  9  cm  apart.
There  were  several  tumour  locations  to  treat  in  11
atients.  In  only  one  case,  it  was  necessary  to  use  two  dif-
erent  approaches  with  ﬁducial  markers  only  used  for  one  of
he  two  lesions.  In  fact,  in  this  case,  the  distance  between
he  two  lesions  was  150  mm.onclusion
BRT  treatment  is  still  being  assessed  in  the  treatment  of
ocal  liver  lesions.  This  technique  is  still  not  very  much  usedG.  Oldrini  et  al.
n  France.  The  radiologist  has  an  important  role  to  play  in
his  treatment  since  the  implant  of  gold  ﬁducial  markers
n  the  liver  is  indispensable.  This  implant  is  almost  always
ossible  with  sonography  guidance,  including  in  lesions
ot  accessible  by  microbiopsy  or  treatment  by  radiofre-
uency  or  in  lesions  poorly  individualised  by  sonography  or
T-scan.
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